Literature DB >> 17179114

Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma.

Kun-Ying Tsai1, Chih-Hsun Yang, Tseng-Tong Kuo, Hong-Shang Hong, John W C Chang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17179114     DOI： 10.1200/JCO.2006.08.6868

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events.

Authors:  Meredith Cummins; Nick Pavlakis
Journal:  Ther Adv Med Oncol       Date:  2013-09       Impact factor: 8.168

Review 2.  Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.

Authors:  Christian Kollmannsberger; Georg Bjarnason; Patrick Burnett; Patricia Creel; Mellar Davis; Nancy Dawson; Darren Feldman; Suzanne George; Jerome Hershman; Thomas Lechner; Amy Potter; Eric Raymond; Nathaniel Treister; Laura Wood; Shenhong Wu; Ronald Bukowski
Journal:  Oncologist       Date:  2011-04-13

Review 3.  [Cutaneous reactions to molecular targeted therapies].

Authors:  C Pföhler; S Ugurel
Journal:  Hautarzt       Date:  2008-10       Impact factor: 0.751

4.  Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.

Authors:  Jian-ri Li; Chi-rei Yang; Chen-li Cheng; Hao-chung Ho; Kun-yuan Chiu; Chung-Kuang Su; Wen-Ming Chen; Shian-Shiang Wang; Chuan-Shu Chen; Cheng-Kuang Yang; Yen-chuan Ou
Journal:  Support Care Cancer       Date:  2012-12-21       Impact factor: 3.603

5.  Blackberry-induced hand-foot skin reaction to sunitinib.

Authors:  Susan L Boone; Gayle Jameson; Daniel Von Hoff; Mario E Lacouture
Journal:  Invest New Drugs       Date:  2008-11-08       Impact factor: 3.850

6.  Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction.

Authors:  Chun-Nan Yeh; Wen-Hung Chung; Shih-Chi Su; Yen-Yang Chen; Chi-Tung Cheng; Yen-Ling Lin; Wan-Chun Chang; Rosaline Chung-Yee Hui; Kun-Chun Chiang; Tsung-Wen Chen; Yi-Yin Jan; Chien-Wei Chen; Ting-Jui Chen; Chih-Hsun Yang; Shuen-Iu Hung
Journal:  J Invest Dermatol       Date:  2014-05-06       Impact factor: 8.551

7.  Novel therapies in advanced renal cell carcinoma: management of adverse events from sorafenib and sunitinib.

Authors:  Philipp Ivanyi; Thomas Winkler; Arnold Ganser; Christoph Reuter; Viktor Grünwald
Journal:  Dtsch Arztebl Int       Date:  2008-03-28       Impact factor: 5.594

Review 8.  Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.

Authors:  S E Rosenbaum; S Wu; M A Newman; D P West; T Kuzel; M E Lacouture
Journal:  Support Care Cancer       Date:  2008-02-15       Impact factor: 3.603

9.  Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Authors:  Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

10.  Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.

Authors:  Xuan Huang; Samir Patel; Nasir Ahmed; Karen Seiter; Delong Liu
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.